Menu
1-702-720-6310 info@microcapspecualtors.com

Cannabis and Biotech Stocks on High Alert

With Cannabis and biotechnology companies currently being the talk of the town, we believe we have located some very interesting firms that present lasting opportunities.  Just a couple weeks ago now Cannabis went mainstream with STZ investing $4 Billion into CGC a legal cannabis company.  

A biotechnology company that we have discovered is ENDV (Endonovo Therapeutics, Inc.).  ENDV is currently flying under the radar of the majority of the street, but we believe ENDV could at any time start receiving major attention from the investing public.  If this is your first-time hearing about ENDV start doing your own research immediately.  ENDV has an FDA-Cleared Electroceutical™ System, SofPulse®, for the palliative treatment of post-operative pain and edema in superficial soft tissues..  Additionally, ENDV recently signed a national distribution agreement for sales, marketing and distribution of SofPulse® targeting the VA, DOD, Indian Health Services, Long Term Care Institutions, Pain Clinics, Wound Clinics and Private Practices among physicians.which is a very positive development.   

These cannabis and biotech companies are on the rise and should be on everyone’s watchlist: Endonovo Therapeutics, Inc. (OTCQB: ENDV), Cara Therapeutics, Inc. (CARA), Insys Therapeutics, Inc. (INSY), and Aphria, Inc. (APHQF)

Endonovo Therapeutics, Inc. (OTCQB: ENDV)

Market Cap: $9.15M, current share price: $0.025

Endonovo Therapeutics (OTCQB: ENDV) is a commercial stage developer of non-invasive medical devices designed to deliver its proprietary Electroceutical™ Therapy.. The Company’s current portfolio of commercial and clinical-stage wearable Electroceuticals™ Therapies addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post-concussion syndrome and multiple sclerosis. The Company’s non-invasive Electroceutical™ System device, SofPulse®, using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company’s current portfolio of pre-clinical stage Electroceuticals™ addresses chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The Company’s non-invasive, wearable Electroceuticals™ work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur.

 

Cara Therapeutics, Inc. (CARA)

Market Cap: $743.73 Share Price: $18.70

Cara Therapeutics, Inc. (CARA), a U.S. biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, announced that it has licensed worldwide rights, except in the U.S., Japan and South Korea, to commercialize KORSUVA (CR845/difelikefalin) injection for the treatment of chronic kidney disease-associated pruritus (CKD-aP) in dialysis patients to Vifor Fresenius Medical Care Renal Pharma Ltd (VFMCRP), a joint company of Vifor Pharma Group (VIFN.VX) and Fresenius Medical Care (FMS) that specializes in treatments for CKD. The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to KORSUVA injection for this indication, for which there are currently no approved therapies in the U.S. or E.U. The stock made a huge jump on second quarter financials.  Since

Insys Therapeutics, Inc. (INSY)

Market Cap: $583.56M Share Price: $7.86

Insys Therapeutics, Inc announced the U.S. Food and Drug Administration declined to approve its opioid painkiller, citing potential safety concerns. Insys’ treatment is an under-the-tongue spray formulation of the opioid buprenorphine that was under review to treat moderate-to-severe pain.  Despite the news the stock has maintained investor interest.  Investors believe the company will bounce back.

Aphria, Inc. (APHQF)

Market Cap: $2.5B Share Price: $10.75

Aphria Inc. recently announced that it has signed a Manufacturer’s Representative agreement with We Grow BC Ltd., a Vancouver -based licensed producer of premium cannabis, to become We Grow’s exclusive sales representative across Canada.  Investors have jumped on this news, making it one of the hottest marijuana plays in the sector.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns Microcapspeculators.com, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] Microcapspeculators.com does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns Microcapspeculators.com, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two.  ACR Communication, LLC has been compensated one thousand dollars cash for this article and sixty one thousand dollars total by Regal Consulting. LLC, for news commentary articles for ENDV.  ENDV and Regal Consulting, LLC were given an opportunity to edit information included in this article.  This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information.  ACR Communication, LLC, will not buy or sell any shares in stocks contained within this article for forty eight hours after this article’s distribution.

For Full Legal Disclaimer Click Here.

Contact Information:

Company Name: Microcap Speculators

Contact Person: Media Manager

Email: info@microcapspecualtors.com

Phone: 1-702-720-6310

Country: United States

Website: http://microcapspeculators.com/

Search